AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00833833
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
Trial: NCT00833833
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dexamethasone
Trial: NCT00833833
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
Trial: NCT02981108
Drug: HS-10296
RxNorm normalized name: HS-10296
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
Trial: NCT02751411
Drug: Macrogol 4000
RxNorm normalized name: Macrogol 4000
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stool softener
Trial: NCT04049734
Drug: oral losatan
RxNorm normalized name: losartan Oral Tablet
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of oral losartan one hour before the ERCP once
Trial: NCT00159133
Drug: antipsychotics vs. Lorazepam (Drugs)
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
Trial: NCT02576301
Drug: Phase 1 - OXi4503 + cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Determination of MTD of the combination of OXi4503 + cytarabine
Trial: NCT02576301
Drug: Phase 2 - OXi4503 + cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
Trial: NCT02576301
Drug: Phase 2 - OXi4503 + cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
Trial: NCT00201786
Drug: Pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
Trial: NCT04027192
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg per day, orally
Trial: NCT00416832
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01530542
Drug: oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxycodone hydrochloride 5 mg tablet under fasted conditions
Trial: NCT01530542
Drug: oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
Trial: NCT01530542
Drug: oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
Trial: NCT01530542
Drug: oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
Trial: NCT01530542
Drug: marketed oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x oxycodone hydrochloride 15 mg tablet under fed conditions
Trial: NCT00416832
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00416832
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00416832
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00416832
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04552483
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
Trial: NCT03456661
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
Trial: NCT03456661
Drug: Levobupivacaine + Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
Trial: NCT02294162
Drug: Ketamine i.v
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00650351
Drug: Ciprofloxacin Extended-Release Tablets 1000 mg
RxNorm normalized name: ciprofloxacin Extended Release Oral Tablet
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg, single dose fed
Trial: NCT06106932
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
Trial: NCT03053739
Drug: Sildenafil 20mg and Bosentan 62.5mg
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
Trial: NCT03053739
Drug: Sildenafil 20mg and Placebo
RxNorm normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
Trial: NCT00641329
Drug: CLONICEL (clonidine HCl sustained release)
RxNorm normalized name: clonidine hydrochloride Extended Release Suspension
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible Dose (0.1 - 0.4 mg)
Trial: NCT02351934
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02351934
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
Trial: NCT01630746
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03740464
Drug: Short-term granulocyte colony stimulating factor
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
Trial: NCT03450187
Drug: TP-271
RxNorm normalized name: TP-271
DrugBank: TP-271 (DB15040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
Trial: NCT01238575
Drug: extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
Trial: NCT03774108
Drug: Metformin Hydrochloride 850 MG
RxNorm normalized name: metformin hydrochloride 850 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8 weeks tratment with oral metformin
Trial: NCT03147092
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of hypertensive subjects
Trial: NCT03147092
Drug: Losartan potassium 50mg
RxNorm normalized name: LOSARTAN POTASSIUM 50MG TAB,UD
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of hypertensive subjects
Trial: NCT03147092
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of hypertensive subjects
Trial: NCT00526474
Drug: Vorapaxar
RxNorm normalized name: Vorapaxar
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5-mg tablet daily for at least 1 year
Trial: NCT02089451
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
Trial: NCT00380887
Drug: Premarin
RxNorm normalized name: Premarin
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02809027
Drug: Ginger
RxNorm normalized name: Ginger
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00326833
Drug: vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 µg vitamin B12 three times daily for two days (CobaSorb)
Trial: NCT01119599
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00553072
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/kg/dose in 1 ml normal saline
Trial: NCT02419807
Drug: Indocyanine Green Solution
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given subdermally
Trial: NCT00191178
Drug: insulin lispro protamine suspension:insulin lispro rDNA origin low mix
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191178
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02977065
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO daily for 4weeks
Trial: NCT02977065
Drug: Atorvastatin 20 mg + CKD-519 50 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO daily for 4weeks
Trial: NCT02977065
Drug: Atorvastatin 20 mg + CKD-519 100 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO daily for 4weeks
Trial: NCT02977065
Drug: Atorvastatin 20 mg + CKD-519 200 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO daily for 4weeks
Trial: NCT01540435
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
Trial: NCT03743285
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Trial: NCT05366101
Drug: Sacubitril/Valsartan
RxNorm normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
Trial: NCT00767975
Drug: isoniazid , randomized, open label
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
Trial: NCT00767975
Drug: rifampin, randomized, open label
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
Trial: NCT01767532
Drug: Cephalexin 125 mg/5ml
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product 20 ml
Trial: NCT01767532
Drug: Cephalexin 125 mg/5ml
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product 20 ml
Trial: NCT00424385
Drug: Gleevec + Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg Sorafenib every day (QD) 300mg Gleevec QD
Trial: NCT02225210
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose:0.4μg.kg-1 Maintenance dose :0.2\~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
Trial: NCT02225210
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05\~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
Trial: NCT02001298
Drug: nitroprusside
RxNorm normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04316351
Drug: Toripalimab + Pemetrexed + Anlotinib
RxNorm normalized name: Toripalimab
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit.
Trial: NCT00809744
Drug: cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, 20 000IU, twice a week, 6 months duration
Trial: NCT01621568
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
Trial: NCT01621568
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
Trial: NCT00670345
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
Trial: NCT03078777
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine will be administered to patients.
Trial: NCT02765802
Drug: Peginterferon Lambda-1A
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00564889
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg weekly taken orally
Trial: NCT00564889
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg daily days 1-21 of a 28 day cycle taken orally with food
Trial: NCT01973244
Drug: somapacitan
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation.
Trial: NCT01973244
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
Trial: NCT01411280
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritalin 10mg, Ritalin 20mg
Trial: NCT00003802
Drug: pyrazoloacridine
RxNorm normalized name: Pyrazoloacridine
DrugBank: Pyrazoloacridine (DB12549)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04061161
Drug: Tiotropium Bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
Trial: NCT00562055
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00562055
Drug: PNU-165442G; [S,S]-reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366002
Drug: Darifenacin
RxNorm normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
Trial: NCT05422664
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with autoimmune related epilepsy were included. After obtaining informed consent, lacosamide was given according to the weight of the patients, and the efficacy and safety were observed.
Trial: NCT00510640
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
Trial: NCT00555594
Drug: Bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One dose of 0.1cc of subconjunctival Bevacizumab was applied
Trial: NCT01344954
Drug: TB-402
RxNorm normalized name: TB-402
DrugBank: TB-402 (DB06050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously over 10 minutes
Trial: NCT01344954
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally as a capsule once a day for 35 days
Trial: NCT04224350
Drug: Tacrolimus cap.
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
Trial: NCT01360710
Drug: Moxonidine
RxNorm normalized name: moxonidine
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2mg/day for 2 weeks, 0.4mg/day for 6 months
Trial: NCT01360710
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
Trial: NCT01683656
Drug: niacin/laropiprant
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00141219
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150-600mg/day, BID
Trial: NCT01994213
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famitinib 25 mg p.o. qd
Trial: NCT00379041
Drug: mechlorethamine hydrochloride
RxNorm normalized name: Mechlorethamine hydrochloride
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379041
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379041
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379041
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00379041
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023894
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no